1	Title: Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review										
2	and meta-analysis of cost-utility studies										
3											
4	Short title: cost-effectiveness of Ezetimibe plus statin therapy an SRMA										
5 6	Authouse Alchil Sociahoron MDII S Sociah Verman DLD Vermals Vermante Level +** DI										
7	Authors: Akhil Sasidharan MPH., S Sajith Kumar, PhD., Kayala Venkata Jagadeesh ^{**} Pharm D., Meenakumari Natarajan, PhD MPH., Bhavani Shankara Bagepally MBBS, PhD [†]										
8	Witemakuman Natarajan, 1 nD wit 11., Dhavam Shankara Dagepany WiDDS, F nD										
9	Authors' Affiliation:										
10	Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology,										
11	Chennai, India										
12	**Health Technology Assessment in India Secretariat, Department of Health Research, Govt of										
13	India, New Delhi.										
14											
15	Corresponding author †										
16	Dr. Bhavani Shankara Bagepally.										
17 18	Scientist-D, ICMR-National Institute of Epidemiology Co-Ordinator, Health Technology Assessment Resource Centre, ICMR-NIE										
10 19	R-127, Tamil Nadu Housing Board, Phase I and II,										
20	Ayapakkam, Chennai-600077										
21	Ph: Off-044-26136316; email: bagepally.bs@gov.in										
22											
23	Word Count:Abstract: 239Manuscript: 4825No of Tables: 1										
24	No of Figures: 2 No. of Suppl. Tables:1 No of Suppl Figures: 14										
25											
26	Key Words: cost-effectiveness, Ezetimibe, PCSK9i, statin, INB										
27											
28	Declaration of Conflict of interest: None										
29	End in a Dart of Harlth Descent Cost of India for the UTADO JOMP NIE Court and										
30 31	Funding: Dept. of Health Research Govt. of India funds the HTARC, ICMR-NIE Grant no: T.11011/08/2017-HR(Part-1)/E-office -8025571 dated 27th Nov-2019. The funders played no role										
32	in the study's conception, execution, or manuscript preparation.										
33	In the study's conception, execution, or manuscript preparation.										
34	Authors Contribution:										
35	Akhil Sasidharan: Conceptualisation, Data curation, Formal analysis, Original draft.										
36	Sajith Kumar: Data curation, original draft, review & editing.										
37	Meenakumari N: Data curation, review & editing.										
38	KV Jagadeesh: Data curation, review & editing.										
39	Bagepally BS: Conceptualisation, Methods, Formal analysis, Software, Review & editing.										
40											
41 42	Acknowledgements: None										
42											
43											
.0											
44											

Page | 1

45 Abstract

46 Introduction: In addition to statin therapy, Ezetimibe, a non-statin lipid-modifying agent, is 47 increasingly used to reduce low-density lipoprotein cholesterol and atherosclerotic cardiovascular 48 disease risk. Literature suggests the clinical effectiveness of Ezetimibe plus statin (EPS) therapy; 49 however, primary evidence on its economic effectiveness is inconsistent. Hence we pooled 50 incremental net benefit to synthesise the cost-effectiveness of EPS therapy.

51 Methods: We identified economic evaluation studies reporting outcomes of EPS therapy 52 compared with other lipid-lowering therapeutic agents or placebo by searching PubMed, Embase, 53 Scopus, and Tufts Cost-Effective Analysis registry. Using random-effects meta-analysis, we 54 pooled Incremental Net Benefit (INB) in the US \$ with a 95% confidence interval (CI). We used 55 the modified economic evaluations bias checklist and GRADE quality assessment for quality 56 appraisal. The review was apriori registered with PROSPERO, CRD42021248531.

Results: The pooled INB from twenty-one eligible studies showed that EPS therapy was significantly cost-effective compared to other lipid-lowering therapeutic agents or placebo. The pooled INB (95% CI) was \$4,274 (621 to 7,927), but there was considerable heterogeneity (I²=84.21). On subgroup analysis EPS therapy is significantly cost-effective in high-income countries [\$4,356 (621 to 8,092)], for primary prevention [\$4,814 (2,523 to 7,106)], and for payers' perspective [\$3,255 (571 to 5,939)], and from lifetime horizon [\$4,571 (746 to 8,395)].

63 Conclusion: EPS therapy is cost-effective compared to other lipid-lowering therapeutic agents or 64 placebo in high-income countries and for primary prevention. However, there is a dearth of 65 evidence from lower-middle-income countries and the societal perspective.

66

- 67
- 68

69 Introduction:

Cardiovascular disease (CVD) and cardiovascular events have a perpetual relationship with 70 hyperlipidemia ¹⁻³. The World Health Organization (WHO) reported that an estimated 17.9 million 71 people died from CVDs in 2019 alone, representing one-third of all global deaths ⁴. For reducing 72 73 cardiovascular events, statin drugs targeting 3-hydroxy-3-methyl-glutaryl-coenzyme (HMG-CoA) 74 reductase are the most prescribed medications ⁵. Statins lower the cardiovascular risk in all groups ⁶⁻⁸, as well as the risk of developing CVD events ^{9, 10}. Despite rigorous statin regimens aimed to 75 76 lower the risk of cardiovascular complications, a large number of statin-treated patients fail to 77 attain the recommended target low-density lipoprotein-cholesterol (LDL-C) levels due to statin 78 intolerance or discontinuation of treatment due to adverse drug reactions 11, 12. Ezetimibe is a non-79 statin lipid-modifying agent targeting the Niemann-Pick C1-like 1 intestinal cholesterol transporter 80 protein (cholesterol absorption inhibitor)^{13, 14}. It is used to achieve the desirable LDL-C levels for 81 patients on maximally tolerated statin therapy. When added to a statin, Ezetimibe achieves a reduction in LDL-C of typically 20–25% with reduced atherosclerotic CVD (ASCVD) risk ^{15, 16}. 82 Hence, the 2018 Cholesterol guidelines warrant using Ezetimibe in individulas with a high 83 ASCVD risk despite receiving optimal statin medication ⁷. Studies showed that Ezetimibe reduced 84 85 LDL-C at levels consistent with Cholesterol Treatment Trialists' (CTT) Collaboration estimates, giving CTTs' extrapolation beyond their initial analysis legitimacy and validity ^{15, 17}. Many 86 professional organisations have recently issued guidelines recommending the use of non-statin 87 88 medications in clinical practice, considering their usefulness ^{3, 18-20}.

Ezetimibe co-administration with statins has resulted in fewer very-high-risk and extremely highrisk patients eligible for other lipid-lowering agents ²¹. A favourable tolerability profile, ease of
use, and affordability make Ezetimibe a better option than PCSK9i ²². Furthermore, a recent metaanalysis of cost-utility studies (CUA) showed PCSK9i to be not cost-effective compared to other

lipid-lowering therapeutic agents in high-income countries (HICs) ^{23, 24}. As a result, Ezetimibe can
be used as a next- cholesterol medication. However, its use and the extent to which it meets unmet
reuirements are limited. The availability of Ezetimibe as a generic drug in several countries ²⁵ can
act as a positive indicator and increase overall access to this medication.

97 Further, the evidence on the cost-effectiveness of this therapy is also inconsistent, as few studies 98 report it is cost-effective ^{26 27}. In contrast, other studies report that combination therapy is not cost-99 effective^{20 28} compared to statin therapy. Hence to provide synthesid evidence, we systematically 100 reviewed the evidence on the cost-effectiveness and quantitatively estimated the pooled 101 incremental net benefit (INB) of ezetimibe therapy.

102

103 METHODS:

The study protocol was pre-registered with PROSPERO, CRD42021248531, and the study was
 conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses
 (PRISMA)²⁹.

107 Data sources, eligibility criteria, screening, and search strategy: We searched PubMed, Embase, Scopus, and the Tufts Medical Centers' cost-effective analysis (CEA) registry³⁰ for 108 109 studies published from inception to 26 April 2021 (see Appendix 1), adhering to the PRISMA 110 guideline. We followed the PICO approach (Population, Intervention, Comparator, Outcome) to 111 construct the search terms. Published Cost-Utility Analysis (CUAs) were eligible if they met all 112 the following inclusion criteria. Adult subjects (age above 18 years) with risk of or established 113 CVD requiring lipid-lowering therapy and treated with Ezetimibe compared to other lipid-114 lowering therapeutic agents such as statins or PCSK9i, or with placebo/no treatment. We included 115 studies reporting economic outcomes in incremental cost-effectiveness ratios (ICER) per quality-

116 adjusted life years (QALYs) or INB. Studies with effectiveness measured other than in quality-117 adjusted life years (QALY), reviews, letters, editorials, abstracts, books, reports, grey literature, 118 and methodological articles were excluded. The detailed search terms are reported in Appendix 1. 119 Selection of studies: We identified a total of 1,944 studies after systematically searching multiple 120 peer-reviewed repositories. All English language studies that met the eligibility criteria listed from 121 the electronic database search were screened independently for titles and abstracts by two 122 independent reviewers (BSB and AS) for their potential inclusion using the Rayyan-web 123 application ³¹. Reviewers (AS, KVJ, and MK) independently reviewed the full text of the finalized 124 125 studies after the title and abstract screening and deduplication in detail. The independent 125 assessors' mutual agreement with another reviewer (BSB) produced the final list of studies meeting 126 the inclusion and exclusion criteria (n=22), and data were extracted from the selected studies. The 127 PRISMA flow chart of the screening process is appended as Figure 1.

128 **Data extraction:** Using a data extraction template adapted for the outcomes of interest, we 129 extracted the following data from eligible studies: author, year, country of setting, study/patient 130 characteristics, intervention, comparator, and the general characterization of the model, which 131 included model type, perspective, time horizons, discount rate, and currency year. We extracted 132 economic parameters such as costs (C), incremental costs (ΔC), clinical effectiveness (E), its 133 incremental effectiveness (ΔE), ICERs, INB values, and their measures of dispersion [i.e., standard 134 deviation (SD), standard error (SE), or 95% confidence interval (CI), willingness to pay (WTP), 135 and threshold (K). From the cost-effective (CE) plane graph, we extracted ΔC and ΔE values using 136 WebPlotDigitaliser³².

137 **The outcome of interest:** In the meta-analysis, we estimated the pooled INB, defined as pooled 138 INB = K* Δ E- Δ C, where K was the WTP threshold, Δ C-incremental cost (i.e., the difference in

139 costs between intervention and comparator), ΔE -incremental effectiveness (i.e., the difference in 140 effectiveness between intervention and comparator). A positive INB favours intervention, i.e., 141 intervention is cost-effective, whereas a negative INB favours the comparator, i.e., intervention is 142 not cost-effective. INB is used instead of ICER as the effect measure because of the inherent 143 limitations of ICER and the ambiguity in interpreting them ³³⁻³⁵.

144 **Data preparation and statistical analysis:** We followed the data preparation method and analysis 145 described and used elsewhere ^{23, 33, 36, 37}. To calculate the INB and its variance, mean values along 146 with dispersions (SD, SE, and 95% CI) of ΔC and ΔE are required. However, economic studies 147 reported different parameters; therefore, we designed five scenarios to deal with the data available 148 from primary studies (Appendix II). Using the data reported in the primary research publications 149 and following the approach detailed in Bagepally et al. ^{33, 36}, we calculated the INB and its variances for each intervention comparator duo. If a cost-effective (CE) plane graph was not 150 151 provided, covariance was estimated for 1000 Monte-Carlo simulations from the extracted ΔC and 152 ΔE values for studies included in scenario 3 (see Appendix II).

153 Included studies reported in different currencies from different time points (years). To compare 154 INB in a common currency, all monetary units, except for the non–GDP-based threshold, were 155 adjusted for inflation using the consumer price index (CPI) and converted to purchasing power parities (PPP)-adjusted US dollar (US \$) for the year 2021, as detailed in Appendix II. Following 156 the data preparation, INBs were pooled across studies stratified by income classification as low-157 158 income (LIC), lower-middle (LMIC), upper-middle (UMIC), and high-income (HIC) countries as per the World Bank classification ³⁸. Meta-analysis was applied to pool the INBs using random-159 160 effects model based on the DerSimonian and Laird method. I² statistics were used to assess 161 heterogeneity, $I^2 > 50\%$ was considered substantial heterogeneity, and Cochrane Q p-value < 0.05

was taken as a cut-off for significant heterogeneity. We did subgroup analysis wherever appropriate to explore the source of heterogeneity and provide subgroup-specific pooled INBs. Subsequently, we assessed the publication bias using funnel plots and Eggers' test. Furthermore, we explored the sources of asymmetry using contour-enhanced funnel plots. All data were prepared using Microsoft Excel version 2019 ³⁹ and analyzed using Stata software version 16 ⁴⁰.

167 **Risk of bias assessment and quality assessment:** Reporting quality was assessed independently 168 by the reviewers using the modified economic evaluation bias (ECOBIAS) checklist ⁴¹. It 169 considers both overall biases (11 items) and model-specific biases, including structure (4 items), 170 data (6 items), and internal consistency (1 item). Each item was rated as applicable, partially 171 applicable, unclear, no, or not applicable (Supplementary Figure 1). GRADE (Grading of 172 Recommendation, Assessment, Development, and Evaluation) was used to assess the quality of 173 evidence and grade recommendations ^{42, 43}. We graded the evidence for the cost-effectiveness of 174 Ezetimibe plus statin (EPS) therapy compared to other lipid-lowering therapeutic agents or a placebo. The certainty of the evidence was rated for EPS therapy in HICs, for primary prevention, 175 176 from a payer's perspective, and over a lifetime horizon. Additionally, the certainty of the evidence 177 was rated for the cost-effectiveness of EPS therapy versus statin monotherapy, for EPS therapy 178 versus statin monotherapy for primary prevention from the payer's perspective as well. This 179 assessment was based on the risk of bias, inconsistency, indirectness, imprecision, publication bias, 180 and other considerations. The quality of the evidence was classified as high, moderate, low, or very low ^{42, 43}. We excluded study design and sample size considerations because the included 181 182 cost-utility studies are model-based.

183 **Results:**

184 General Characteristics of the Included Studies: We retrieved and included twenty-two

185 potentially relevant articles^{20, 26-28, 44-61} for systematic review, of which 21 studies were eligible for meta-analysis^{20, 26-28, 44-46, 48-61} (Figure 1). One study from the UK, Ara et al. ⁴⁷, was not included 186 187 for meta-analysis due to incomplete data. The general characteristics of the included articles are 188 summarised in Table 1. Included studies reported 25 comparisons; EPS therapy versus statin monotherapy(n=18)^{26-28, 44, 46, 48-50, 52-55, 58-61}, EPS therapy versus PCSK9i plus Ezetimibe and 189 statins(n=3)^{20, 56, 57}, EPS therapy versus PCSK9i with statin therapy(n=2)^{44, 60} and EPS therapy 190 191 versus no treatment or placebo(n=2)^{45, 51}. All studies were set in HICs, except two, based on 192 UMICs^{28, 59}. Most of the studies (n = 20) analysed a lifetime horizon, except two studies^{51, 59}. Fourteen studies reported from a healthcare perspective^{26, 28, 44-46, 51, 53-56, 58-60}, four from paver's 193 perspective^{20, 27, 48, 52}, and three studies from a societal perspective^{28, 49, 50}. All studies used Markov 194 195 models with acycle length of one year, except for an alongside trial⁵¹. The named models included were Cardio Vascular Disease Policy Model (CVDPM) $(n = 3)^{44, 53, 60}$ and the COOK model $(n = 3)^{44, 53, 60}$ 196 2)^{26, 52}. All studies used discounting for cost and outcomes. All of the included studies reported 197 198 direct medical costs; besides, Kongpakwattana et al. reported direct non-medical costs²⁸, and 199 Landmesser et al. reported indirect costs²⁰. All the studies reported using country-specific thresholds as WTP except one study⁵⁹ that used GDP-based WTP. 200

In the meta-analysis, due to the differences in reported outcomes among different studies, the INB variance from the most comparable studies was utilised for calculations under scenario five (Appendix II). The INB variance of Van Nooten et al. ⁵⁰ was used for three studies ^{20, 49, 54}, and the INB variance of Schlackow et al. ⁵⁸ was used for six studies ^{26, 27, 45, 46, 51, 55}, respectively. Among the 21 studies evaluating the cost-effectiveness of Ezetimibe versus other lipid-lowering therapeutic agents or placebo, seven were set in Europe ^{20, 27, 49, 50, 56, 57, 61}; five were set in the US ^{44, 48, 52, 53, 58, 60}, three in the UK ^{46, 47, 51} and one studies each from Canada ²⁶, China ⁵⁹, Saudi Arabia

⁵⁵ and Thailand ²⁸. Schlackow et al. reported from the health system perspective of both the US 208 and UK 58. In all studies, except Kongpakwattana et al. 28 and Almalki et al. 55 mean plasma LDL-C 209 210 levels less than 70 mg/dL reflected current ezetimibe dosing recommendations. Except for two⁴⁸, 211 ⁴⁹ that included fatal and non-fatal stroke as well, all studies included fatal and non-fatal coronary heart diseases in their model. Unstable angina was modelled in three studies^{48, 49, 55} in which 212 Almalki et al.⁵⁵ considered coronary revascularisation also. Eventhough three studies^{44, 53, 60} 213 214 modelled adverse events as consequences, only Yang et al.⁵⁹ included costs due to adverse events. Six studies profiled the model population after local registries and databases^{44, 49, 52, 53, 60, 61}, three 215 studies ^{48, 55, 59} from clinical trials, only Kongpakwattana et al. used data from a meta-analysis of 216 217 RCTs²⁸ (see Table 1).

218 All three studies from payers' perspective ^{27, 48, 52}, and seven studies out of nine from the healthcare perspective ^{26, 28, 46, 53-55, 58-60} and two out of three studies from the societal perspective ^{49, 50} reported 219 220 EPS therapy to be cost-effective compared with statin monotherapy. From the healthcare perspective, all two studies ^{44, 60} considered EPS therapy to be cost-effective compared to PCSK9i 221 222 with statin therapy, but only one study⁵⁶ out of three, reported EPS therapy to be cost-effective 223 compared with PCSK9i along with Ezetimibe and statin. The alongside trial ⁵¹, which compared 224 EPS therapy and placebo, reported that the intervention was not cost-effective. In contrast, a 225 model-based study ⁴⁵ that compared EPS therapy versus no treatment reported the intervention as cost-effective. In addition, according to the WTP threshold of Thailand, Kongpakwattana et al.²⁸ 226 227 reported Ezetimibe as not cost-effective from healthcare or societal perspective. Three studies did not report any sensitivity analyses ^{48, 53, 61} while the remaining studies ^{20, 26-28, 44-46, 49, 50, 52, 54-56, 59,} 228 229 ⁶⁰ includeddeterministic as well as probabilistic sensitivity analyses. Additionally, eight studies ²⁸, 44-46, 50, 54, 55, 60 reported scenario and threshold analyses, and six studies ^{26, 49, 51, 52, 56, 60} also included 230

sub-group analyses.

I. Quality Appraisal:

233 **Risk of bias assessment:** The risk of bias among the identified studies was analysed using the 234 ECOBIAS checklist⁶². The ECOBIAS checklist shows that almost 91 percent of the studies chose 235 the best current practice as a comparator, and all the comparators are adequately described. The 236 details of the data used in the studies are transparent. All studies provided sufficient detail on the 237 costs, effectiveness, discount rates, and have acknowledged te sources of of funding. Additionally, 238 model selection bias was negligible. Similarly, bias related to time horizon was also low since 239 majority of the studies employed a lifetime horizon. Limited scope bias is highly probable in 240 almost all studies, also internal consistency related to mathematical logic was not evident 241 (Supplementary Figure 1).

Publication bias: The funnel plot showed asymmetry. The studies were distributed along with the mean effect size of the funnel plot. The Egger's test with a higher p-value (p = 0.860) indicates no significant variability among the studies and no publication bias. However, the absence of studies in the area of significance on the contour enhanced funnel plot suggests the possibility of publication bias due to factors other than non-reporting bias (Supplementary Figure 2). Due to high heterogeneity, it would be difficult to distinguish between publication bias and other causes.

248 II. Ezetimibe compared with other lipid-lowering therapeutic agents or placebo249

The pooled INB (INBp) with 95% CI, \$4,274 (621 to 7,927) showed EPS therapy is significantly cost-effective compared with other lipid-lowering therapeutic agents or placebo. The INBp calculated from 25 comparisons^{20, 26-28, 44-46, 48-61} revealed considerable heterogeneity ($I^2 = 84.21$) (Figure 2).

254 Subgroup analysis: We conducted subgroup analyses to explore the heterogeneity between

255 studies and provide subgroup specific pooled INBs. Subgroup analysis based on treatment 256 comparisons showed that EPS therapy is significantly cost-effective compared with PCSK9i plus 257 statin therapy $(n = 2)^{44, 60}$ with INBp \$66,001 (46,284 to 85,718). Also, EPS therapy is significantly 258 cost-effective compared to PCSK9i plus EPS therapy $(n = 3)^{20, 56, 57}$ with INBp \$6,002 (3,578 to 259 8,427). There was no heterogeneity ($I^2 = 0.0$) in either of the subgroups. However, EPS therapy is not significantly cost-effective compared to statin monotherapy $(n = 18)^{26-28, 44, 46, 48, 49, 52-55, 58-61}$ 260 261 with INBp 2,558 (-1,249 to 6,364) and considerable heterogeneity (I² = 84.02). Likewise, EPS therapy is not significantly cost-effective compared to no treatment or placebo $(n = 2)^{45, 51}$ with 262 INBp \$18.4 (-12.093 to 12.130) and no heterogeneity ($I^2 = 0.0$) (Supplementary Figure 3). 263

On subgroup analysis with the income status of the countries, the pooled INBs from HICs (n = $22)^{20, 26, 27, 44-46, 48-58, 60, 61}$ showed that EPS therapy is cost-effective compared with other lipidlowering therapeutic agents or placebo with an INBp of \$4,356 (621 to 8,092) with considerable heterogeneity (I² = 86.18). In contrast, EPS therapy is not significantly cost-effective for the UMICs^{28, 59} with an INBp of \$1,140 (-18,959 to 21,239) and no heterogeneity (I² = 0.0) (Supplementary Figure 4).

270 On subgroup analysis with study perspective, the pooled INBs among studies from payers' 271 perspective $(n = 4)^{20, 27, 48, 52}$ showed that EPS therapy is significantly cost-effective compared with 272 other lipid-lowering therapeutic agents or placebo with an INBp of \$3,255 (571 to 5,939) but with substantial heterogeneity ($I^2 = 71.14$). However, EPS therapy is not significantly cost-effective 273 from a healthcare perspective $(n = 17)^{26, 28, 44-46, 51, 53-56, 58-61}$ with INBp \$3,255 (571 to 5,939) and 274 considerable heterogeneity ($I^2 = 86.14$) or from a societal perspective (n = 3)^{28, 49, 50} with INBp 275 276 3,255 (571 to 5,939) and considerable heterogeneity (I² = 86.04) (Supplementary Figure 5). On subgroup analysis based on the time horizon of the study $(n = 23)^{20, 26-28, 44-46, 48-50, 52-58, 60, 61}$, 277

EPS therapy is significantly cost-effective compared with other lipid-lowering therapeutic agents or placebo with an INBp of \$4,571 (746 to 8,395) but with substantial heterogeneity ($I^2 = 85.50$). However, among studies with a non-lifetime horizon, EPS therapy is not significantly costeffective with an INBp of \$381 (-10,332 to 11,093)^{51, 59} and no heterogeneity ($I^2 = 0.0$) (Supplementary Figure 6).

Subgroup analysis based on discount rates of 3% (n = 15)^{20, 28, 44, 49, 52, 53, 55-58, 60} with INBp \$1,879 (-4,547 to 8,305), 3.5% (n = 5) ^{46-48, 51, 58} with INBp \$735 (-1,309 to 2,778) and 5% (n = 2)^{26, 27} with INBp \$2,342 (-9,770 to 14,453) showed EPS therapy is not significantly cost effective compared to other lipid-lowering therapeutic agents or placebo. The 3% discount rate subgroup had considerable heterogeneity (I² = 86.27), but the 3.5% and 5% discount rates subgroup had no heterogeneity (I² = 0.0). However, with a discount rate of 4% (n = 3)^{50, 54, 61}, EPS therapy is

significantly cost-effective with an INBp of \$12,254 (4,448 to 20,060) and considerable

290 heterogeneity ($I^2 = 93.52$) (Supplementary Figure 7).

289

EPS therapy is significantly cost-effective for primary prevention $(n = 7)^{27, 46, 47, 50, 51, 58}$ with an INBp of \$4,814 (2,523 to 7,106) and no heterogeneity (I² = 0.0). However, the pooled INBs showed that EPS therapy is not significantly cost-effective for secondary prevention $(n = 15)^{20, 28}$, 44, 48, 49, 53-57, 59, 60 with an INBp of \$2,088 (-3,282 to 7,457) and considerable heterogeneity (I² = 87.32). Similarly, for primary and secondary prevention together $(n = 3)^{26, 52, 61}$ INBp \$15,257 (-10,035 to 40,550) with considerable heterogeneity (I² = 94.32) showed EPS therapy is not significantly cost-effective (Supplementary Figure 8).

The thresholds used in the comparisons ranged from PPP adjusted \$13,218 to \$2,05,198. Based on the median threshold of \$50,000, the mean INBp among both the subgroups, viz., thresholds of >50,000\$ (n = 13)^{20, 27, 44, 46, 53, 54, 56-58, 60, 61} with INBp \$7,398 (-1,657 to 16,452) and considerable heterogeneity ($I^2 = 89.62$) and thresholds of <50,000 \$ (n = 12) ^{26, 28, 45, 48-52, 55, 58, 59}, INBp \$1,886 (-2 to 3,775) with moderate heterogeneity ($I^2 = 36.66$) showed EPS therapy is not cost effective compared with other lipid-lowering therapeutic agents or placebo, but without statistical significance (Supplementary Figure 9).

305 On subgroup analysis based on scenario, the mean INBp showed EPS therapy is not significantly 306 cost effective compared with other lipid-lowering therapeutic agents or placebo for scenarios two 307 $(n = 6)^{44, 53, 57, 60}$ with an INBp of \$-522 (-59,813 to 58,769) and considerable heterogeneity (I² = 93.99). Under scenarios three $(n = 3)^{58, 61}$ with INBp \$14,398 (-12,225 to 41,020) and with 308 considerable heterogeneity ($I^2 = 87.92$) and four (n = 5)^{28, 48, 50, 56, 59} with INBp \$2,876 (-568 to 309 310 $(I^2 = 48.81)$, EPS therapy was not significantly cost effective 311 compared with other lipid-lowering therapeutic agents or placebo. However, under scenario five $(n = 11)^{20, 26-28, 45, 46, 49, 51, 52, 54, 55}$, EPS therapy was significantly cost effective with INBs of \$3,102 312

313 (599 to 5,606) and substantial heterogeneity ($I^2 = 56.67$) (Supplementary Figure 10).

314 Further subgroup analysis was conducted to explore the heterogeneity observed when EPS therapy 315 was compared with statin monotherapy. We found that compared with statin monotherapy, EPS therapy is significantly cost-effective for primary prevention $(n = 5)^{27, 46, 50, 58}$ with an INBp \$4,992 316 317 (2,659 to 7,326) and no heterogeneity ($I^2 = 0.0$). Also, from a payers' perspective (n = 3) ^{27, 48, 52} 318 with INBp \$2,029 (72 to 3,987) and less heterogeneity ($I^2 = 28.65$) EPS therapy is significantly 319 cost-effective compared with statin monotherapy. However, EPS therapy was cost-effective but 320 without statistical significance among the subgroups of HICs (n = 15) with INBp \$2,574 (-1,341) to 6,488) and with substantial heterogeneity ($I^2 = 86.83$), UMICs (n = 3) with INBp \$1,140 (-321 322 18,959 to 21,239) with no heterogeneity ($I^2 = 0.0$). Similar results were also observed in healthcare perspective $(n = 12)^{26, 28, 44, 47, 53-55, 58-61}$ with INBp \$-323 (-12,568 to 11,922) and substantial 323

heterogeneity ($I^2 = 86.40$), societal perspective (n = 3) ^{28, 49, 50} with INBp \$1,961 (-4,300 to 8,222) with substantial heterogeneity ($I^2 = 86.04$), primary and secondary prevention together (n = 3) ^{26, 52, 61} with INBp \$15,257 (-10,035 to 40,550) with substantial heterogeneity ($I^2 = 94.32$) and lifetime horizon (n = 17)^{26-28, 44, 46, 48, 49, 52-55, 58, 60, 61} with INBp \$2,589 (-1,293 to 6,471) with substantial heterogeneity ($I^2 = 84.95$). For secondary prevention (n = 10)^{28, 44, 48, 49, 53-55, 59, 60} INBp \$-2,303 (-7,728 to 3,123) showed that EPS therapy is not cost-effective compared to statin monotherapy but without statistical significance and substantial heterogeneity ($I^2 = 84.65$).

331 **Certainty of evidence**: The GRADE quality assessment revealed low confidence in the overall 332 evidence of the cost-effectiveness of EPS therapy when compared with other lipid-lowering 333 therapeutic agents or placebo. We found moderate confidence in results for HICs and a low level 334 of confidence in primary prevention. However, the confidence of results from a payer perspective 335 and lifetime horizon is very low. Considering EPS therapy compared with statin monotherapy, we 336 have moderate confidence in the results observed for primary prevention and from the payers' 337 perspective, as detailed in Appendix IV.

338

339 Discussion:

The current study synthesized the cost-effectiveness of Ezetimibe with statin compared to other lipid-lowering therapeutic agents or placebo using systematic review and meta-analysis of costutility studies. Economic evaluation studies are difficult to synthesise due to the differences in economic parameters, income thresholds, study perspectives, costs. Many studies that report costeffectiveness ignore the CI of the ICER point estimates. To address these issues, we tried to standardise data extraction and preprocessing from various published studies to produce a pooled INB with CI.

347 The pooled INBs from 25 comparisons identified from 21 studies for the meta-analysis show that 348 EPS therapy is more cost-effective than other lipid-lowering therapeutic agents such as statins, 349 PCSK9i, placebo, or no treatment. Subgroup analysis strengthened the robustness of our findings. 350 We conducted a subgroup analysis to understand the considerable heterogeneity. EPS therapy is 351 significantly cost-effective compared to PCSK9i plus statin and PCSK9i plus Ezetimibe with 352 statins. A plethora of evidence has shown that the main reasons for the underuse of statins in 353 LMICs and UMCs by eligible patients with established CVD^{63, 64} were lack of availability, 354 accessibility, and affordability. The subgroup analysis also revealed that EPS therapy is cost-355 effective against therapeutic agents or placebo in HICs, with payers' perspective, lifetime horizon, 356 and primary prevention. However, the results lose their robustness and become not significantly 357 cost-effective for HICs and lifetime horizons when we limit the comparator to statin monotherapy 358 alone in further subgroup analysis.

Previous systematic review by Marquina et al. ⁶⁵, had indicated that Ezetimibe was cost-effective in 62.5% of the included studies, and Suh et al. ⁶⁶, indicated that Ezetimibe was cost-effective for stain intolerant patients with chronic kidney disease. With the current evidence, we conclude EPS therapy is not cost-effective for secondary prevention, similar to previously published studies that suggested that PCSK9i may become cost-effective for secondary prevention ⁶¹ only if the WTP threshold is increased or if the drugs cost is lowered ^{44, 60}.

For Ezetimibe, the main cost-effectiveness drivers were baseline cardiovascular risks ^{26, 45, 46, 48, 51, 55}, cost of the drug ^{44, 52, 54, 60}, treatment effects related to cardiovascular and non-cardiovascular mortality ^{28, 52}, and time horizon ^{44, 55, 59}. For some other studies, the cost-effectiveness of EPS therapy compared with statin monotherapy was subject to certain conditions. Davies et al. ⁵² reported that EPS therapy was cost-effective for secondary prevention of CHD and stroke. Also,

370 the study reported that for primary prevention of CHD and stroke in patients whose LDL-C levels 371 were > 100 mg/dL and in patients with diabetes, Ezetimibe becomes cost-effective only if we consideri a 90% cost reduction.. Soini et al. ⁴⁹ showed that EPS therapy is cost-effective only in 372 373 specific sub-populations of men and diabetic women. A study by Ara et al. ⁴⁶ reported that EPS 374 therapy becomes cost-effective in the UK health system when using a threshold of £30,000 per QALY instead of the £20,000 per QALY value. Similarly, Almalki et al. 55 reported that EPS 375 376 therapy was not cost-effective for 5 and 10 year models but became a cost-effective treatment 377 when a lifetime horizon is used.

The drug price and WTP per additional QALY play an important role in determining the costeffectiveness of EPS therapy. The differences observed in reported outcomes and the high heterogeneity estimated among the studies may be the result of changes in drug prices or cost estimations under different study perspectives. This necessitates the need for context-specific future research in primary economic evaluations for EPS therapy compared with different lipidlowering therapeutic agents with a more accurate estimate of costs. More studies from LMICs and societal perspectives are also needed for the generalisability of results.

385 The limitation of our study is that the comprehensiveness of this cost-effectiveness results is 386 arguable since most clinical data comes from western countries, which are set in HICs, which 387 determine the cost of long-term treatment and prescriptions. Only a small percentage comes from 388 Asian studies and none from Africa, Australia, or South America, indicating the need for more 389 studies using LMICs and societal perspectives. A Majority of the studies have not included indirect 390 costs nor. And none captured the real-world burden of CVD or considered out-of-pocket 391 expenditure and caregiver time and costs. The use of surrogate markers even when clinical 392 endpoints areis recommended⁶⁷, t shows lack of clinical trials describing complex outcomes and

393 have increased the uncertainties in the models. The use of clinical trials to model event rates could 394 lead to an underestimation of the baseline risk and the treatment effect, as shown in Lindh et al. ⁶⁸. 395 The mean age reported in majority of the studes was above 60 years. Although LDL-C poses a 396 cumulative risk, lowering LDL-C levels does not always result in a reduction in cardiovascular 397 risk, and prolonged exposure to lower LDL-C from an early point in life substantially reduces the risk of CHD ⁶⁹. Given the focus on populations with established CVD, most studies did not 398 399 examine the effects of treatment initiation at different ages. Moreover, some models used statin 400 trial data to model baseline cardiovascular risk, while others used local demographic data.

401 Another limitation is that we used funnel plots to examine publication bias because we had no 402 specific measures for non-normally distributed INB. We used the GRADE approach to assess the 403 outcome quality because there were no specific GRADE guidelines for cost-utility studies, and the 404 current approach had its limitations ⁷⁰. We could not discern a clear trend regarding whether using 405 data from clinical trials instead of observational studies in terms of baseline risk and treatment 406 effect improves the cost-effectiveness results.. The structural variation among studies could also 407 raise the overall conclusion's uncertainty. Many of these models are not publicly available which limits the ability to compare between settings and countries ⁷¹. Only four studies ^{44, 53, 59, 60} included 408 409 adverse events. Adherence was not modelled in any studies, even when lower adherence rates 410 have been shown to result in poorer health outcomes and higher costs for healthcare systems time 411 after time⁷²When extrapolated to other healthcare contexts, the generalisability of these results 412 should be done with careful consideration. Further, due to limited informationprovided, the costs 413 for co-morbidities and gender differences could not be explored.

414 CONCLUSION: This systematic review and meta-analysis concluded that EPS therapy is a
415 significant cost-effective option compared to other lipid-lowering therapeutic agents or placebo.

416	The subgroup analysis supported the findings in HICs, from payers' perspective, for primary
417	prevention and for the lifetime horizon. However, the robustness of the results is lost for HICs and
418	lifetime horizon when EPS therapy is compared with statin monotherapy alone, where it is not
419	significantly cost-effective. The GRADE quality assessment revealed moderate confidence in the
420	results observed in HICs for EPS therapy compared to other lipid-lowering therapeutic agents or
421	placebo and statin monotherapy. The majority of the studies were from HICs and undertook a
422	healthcare perspective, highlighting a lacuna in evidence to be filled from a societal perspective
423	and LMICs.
424	
425	
426	
427	

				5							
Author_year	Country	Setting	Perspective	Target population	Time Horizon	Discount Rate	Reference year	Intervention	Comparator	Prevent ion	Remarks
Kohli_2006 ²⁶	Canada	Risk Group	Healthcare	CAD & non-fatal CAD (angina or acute MI)	Lifetime	5	2002	Ezetimibe+ Statin	Statin	PP+SP	Cost effective
Ara_2008 ^{1 45}	UK	Country	Healthcare	Primary Hypercholesterolemia	Lifetime	3.5	2006	Ezetimibe+ Statin	No Treatment	РР	Cost effective
Ara_2008 ² ⁴⁶	UK	Risk Group	Healthcare	Primary Hypercholesterolemia	Lifetime	3.5	2006	Ezetimibe+ Statin	Statin	РР	Cost effective
Ara_2008 ^{3 47} *	UK	Risk Group		ACS	Lifetime	3.5	2006	Ezetimibe+ Statin	Statin		Cost effective
Reckless_2010 ⁴⁸	USA	Risk group	Payer	Non-fatal CHD with or without DM	Lifetime	3.5	2004	Ezetimibe+ Statin	Statin	SP	Cost effective
Soini_2010 49	Finland	Risk group	Societal	Primary Hypercholesterolemia	Lifetime	3	2007	Ezetimibe+ Statin	Statin	SP	Cost effective
Nooten_2011 50	Netherland	Country	Societal	High CVD risk, history of CHD and/or DM	Lifetime	4	2008	Ezetimibe+ Statin	Statin	РР	Cost effective
Laires_2015 27	Portugal	Country	Payer	CKD but without known CHD	Lifetime	5	2015	Ezetimibe+ Statin	Statin	РР	Cost effective
Mihaylova_2016	UK	Country	Healthcare	HeterozygousFH/ Preexisting ASCVD	Non- Lifetime	3.5	2015	Ezetimibe+ Statin	No Treatment	РР	Not Cost effective
Kazi_2016 ^{a 44}	USA	Country	Healthcare	HeterozygousFH/ Preexisting ASCVD	Lifetime	3	2015	Ezetimibe+ Statin	Statin	SP	Cost effective
Kazi_2016 ^{b 44}	USA	Country	Healthcare	ASCVD	Lifetime	3	2015	Ezetimibe+ Statin	PCSK9i+ Statin	SP	Cost effective
Kazi_2017 53	USA	Risk Group	Healthcare	ACS	Lifetime	3	2017	Ezetimibe+ Statin	Statin	SP	Cost effective
Almalki_2017 55	Saudi Arabia	Country	Healthcare	CVD history (both CHD and stroke).	Lifetime	3	2016	Ezetimibe+ Statin	Statin	SP	Cost effective
Davies_2017 52	USA	Country	Payer	CAD & non-fatal CAD (angina or acute MI)	Lifetime	3	2013	Ezetimibe+ Statin	Statin	PP+SP	Cost effective
Stam-Slob _2017 54	Netherland	Risk group	Healthcare	stable CAD	Lifetime	4	2014	Ezetimibe+ Statin	Statin	SP	NA
Korman_2018 61	Norway	Country	Healthcare	Hypercholesterolemia, DM, Statin Intolerant	Lifetime	4	2015	Ezetimibe+ Statin	Statin	PP+SP	Cost effective
Stam-Slob_2018 56	Netherland	Risk group	Healthcare	FH without a history of vascular disease, stable vascular disease, DN	Lifetime	3	2014	Ezetimibe+ Statin	PCSK9i+ Ezetimibe+ Statin	SP	NA
Kongpakwattana_ 2019 ^{a 28}	Thailand	Country	Societal	Existing CVD, comprising MI and stroke	Lifetime	3	2018	Ezetimibe+ Statin	Statin	SP	Not Cost effective
Kongpakwattana_ 2019 ^{b 28}	Thailand	Country	Healthcare	Existing CVD, comprising MI and stroke	Lifetime	3	2018	Ezetimibe+ Statin	Statin	SP	Not Cost effective

Table1 –	Character	istics of	identified	studies	for Sys	stematic I	Review
							-

Author_year	Country	Setting	Perspective	Target population	Time Horizon	Discount Rate	Reference year	Intervention	Comparator	Prevent ion	Remarks
Kazi_2019 a 60	USA	Country	Healthcare		Lifetime	3	2018	Ezetimibe+	Statin		Cost effective
				ACS				Statin		SP	
Kazi_2019 ^{b 60}	USA	Country	Healthcare		Lifetime	3	2018	Ezetimibe+	PCSK9i+		Cost effective
				ACS				Statin	Statin	SP	
Schlackow_2019	USA	Risk	Healthcare		Lifetime	3	2015	Ezetimibe+	Statin		Cost effective
a 58		group		Non dialysis patients with CKD				Statin		PP	
Schlackow_2019	UK	Risk	Healthcare		Lifetime	3.5	2015	Ezetimibe+	Statin		Cost effective
b 58		group		Non dialysis patients with CKD				Statin		PP	
Dressel_2019 57	Germany	Country			Lifetime	3	2018	Ezetimibe+	PCSK9i+		Not Cost
								Statin	Ezetimibe+		effective
				Stable CAD					Statin	SP	
Landmesser_202	Sweden	Risk	Payer		Lifetime	3	2019	Ezetimibe+	PCSK9i+		Not Cost
0 20		group		Recent MI /MI with a second event/MI				Statin	Ezetimibe+		effective
				with a risk factor					Statin	SP	
Han Yang_2020	China	country	Healthcare		Non-	3	2017	Ezetimibe+	Statin		Cost effective
59				Newly diagnosed with CVD	Lifetime			Statin		SP	

*Not included in meta-analysis, PP-primary prevention, SP-secondary prevention, PP+SP- both primary and secondary prevention

References

- 1. Karr S. Epidemiology and management of hyperlipidemia. The American Journal of Managed Care 2017;23(9 Suppl):S139-S148.
- Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA 2018;319(15):1566-1579.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014;63(25 Part B):2889-2934.
- 4. Organisation Wh. Cardiovascular diseases (CVDs). In: WHO.
- 5. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet 2015;385(9976):1397-1405.
- 6. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344.
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2019;73(24):3168-3209.
- 8. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England) 2012;380(9841):581-590.
- 9. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-Term Benefit of Statin Therapy Initiated??during Hospitalization for??an??Acute??Coronary Syndrome: A Systematic Review of Randomized Trials. American Journal of Cardiovascular Drugs 2007;7(2):135-141.
- 10. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338(jun30 1):b2376-b2376.
- 11. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology 2014;64(5):485-494.
- 12. Tataronis GR. Statin-Related Adverse Events: A Meta-Analysis. Clinical Therapeutics 2006;28(1).


- 13. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. British journal of clinical pharmacology 2002;54(3):309-319.
- 14. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106(15):1943-1948.
- 15. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine 2015;372(25):2387-2397.
- 16. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223(2):251-261.
- 17. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health economics 2005;14(4):339-347.
- Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Journal of the American College of Cardiology 2017;70(14):1785-1822.
- 19. Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, et al. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. Journal of clinical lipidology 2017;11(4):880-890.
- 20. Ulf Landmesser PL, Emil Hagstro^m, Ben van Hout, Guillermo Villa PP-R, Jorge Arellano, Maria Eriksson Svensson, Mahendra Sibartie, and Gregg C Fonarow. Costeffectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European heart journal Quality of care & clinical outcomes 2020.
- 21. Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. Journal of clinical lipidology 2019;13(4):525-537.
- 22. Chaiyasothi T, Nathisuwan S, Dilokthornsakul P, Vathesatogkit P, Thakkinstian A, Reid C, et al. Effects of non-statin lipid-modifying agents on cardiovascular morbidity and mortality among statin-treated patients: a systematic review and network meta-analysis. Frontiers in pharmacology 2019;10:547.
- 23. Bagepally BS, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology 2021.
- 24. Arbel R, Hammerman A, Azuri J. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Am J Cardiol 2019;123(8):1273-1276.
- 25. Qamar A, Giugliano RP, Bohula EA, Park J-G, Jarolim P, Murphy SA, et al. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. Journal of the American College of Cardiology 2019;74(8):1057-1068.
- 26. Kohli M, Attard C, Lam A, Huse D, Cook J, Bourgault C, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics 2006;24(8):815-830.

- 27. Laires PA, Ejzykowicz F, Hsu T-Y, Ambegaonkar B, Davies G. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. J Med Econ 2015;18(8):565-572.
- 28. Kongpakwattana K, Ademi Z, Chaiyasothi T, Nathisuwan S, Zomer E, Liew D, et al. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. PharmacoEconomics 2019;37(10):1277-1286.
- 29. Moher D SL, PRISMA-P Group,. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4(1):1.
- 30. Registry C. Center for the Evaluation of Value and Risk in Health. In.
- 31. Ouzzani M HH, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5(1):210.
- 32. Rohatgi A. WebPlotDigitizer. In. USA; 2021.
- 33. Bagepally BS, Gurav YK, Anothaisintawee T, Youngkong S, Chaikledkaew U, Thakkinstian A. Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis. Value Health 2019;22(12):1458-1469.
- 34. Paulden M. Why it's Time to Abandon the ICER. Pharmacoeconomics 2020;38(8):781-784.
- 35. O'Mahony JF. The Limitations of Icers In Screening Interventions and The Relative Net Benefit Alternative. Value in Health 2015;18(7).
- 36. Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaiyakunapruk N, et al. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care 2020;8(1).
- 37. Crespo C, Monleon A, Díaz W, Ríos M. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC medical research methodology 2014;14(1):1-9.
- 38. Bank TW. World Bank Country and Lending Groups World Bank Data Help Desk. In; 2021.
- 39. Corporation. M. Microsoft Excel [Internet]. In; 2018.
- 40. StataCorp. Stata Statistical Software: Release 16. In. 16 ed: College Station, TX: StataCorp LLC.; 2019.
- 41. Adarkwah CC vGP, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16(4):513-523.
- 42. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-394.
- 43. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology 2017;87:4-13.
- 44. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Costeffectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA 2016;316(7):743.
- 45. Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs 2008;8(6):419-427.
- 46. Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy

compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries. Clin Ther 2008;30(8):1508-1523.

- 47. Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, et al. Ezetimibe for the treatment of hypercholesterolaemia: A systematic review and economic evaluation. Health Technol Assess 2008;12(21):1-92.
- 48. Reckless J, Davies G, Tunceli K, Hu XH, Brudi P. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: Findings from the INFORCE study. Value Health 2010;13(6):726-734.
- 49. Soini EJO, Davies G, Martikainen JA, Hu HX, Tunceli K, Niskanen L. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26(1):25-36.
- 50. F. van Nooten GMD, J. W. Jukema, A. H. Liem, E. Yap, X. H. Hu. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2011;19(2):61-7.
- 51. Mihaylova B S, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R, Cass A, Craig J, Gray A, Collins R, Landray M, C B. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American journal of kidney diseases : the official journal of the National Kidney Foundation 2016;67(4):576-84.
- 52. Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. J Med Econ 2017;20(7):723-731.
- 53. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, et al. Updated costeffectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 2017;318(8):748-750.
- 54. Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JAN, Visseren FLJ. Costeffectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary artery disease patients. Journal of the American Heart Association 2017;6(2).
- 55. Almalki ZS, Guo JJ, Alahmari A, Alotaibi N, Thaibah H. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, Lung and Circulation 2018;27(6):656-665.
- 56. Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ. Costeffectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 2018;253:148-154.
- 57. Dressel A, Schmidt B, Schmidt N, Laufs U, Fath F, Chapman MJ, et al. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. Vasc Pharmacol 2019;120.
- 58. Iryna Schlackow SK, William Herrington3, Jonathan Emberson, Richard Haynes, Christina Reith, Rory Collins, Martin J. Landray, Alastair Gray, Colin Baigent and Borislava Mihaylova Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International 2019;96(1):170-179.
- 59. Yang H, Li N, Zhou Y, Xiao Z, Tian H, Hu M, et al. Cost-effectiveness analysis of Ezetimibe as the add-on treatment to moderate-dose rosuvastatin versus high-dose rosuvastatin in the secondary prevention of cardiovascular diseases in China: A Markov model analysis. Drug Des Dev Ther 2020;14:157-165.

- 60. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. Annals of Internal Medicine 2019;170(4):221.
- 61. Korman M, Wisløff T. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. European Heart Journal Cardiovascular Pharmacotherapy 2018;4(1):15-22.
- 62. Adarkwah CC, van Gils PF, Hiligsmann M, Evers SM. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res 2016;16(4):513-23.
- 63. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine Lists, price, availability, and affordability. Journal of the American Heart Association 2020;9(9):e015302.
- 64. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to medications for cardiovascular diseases in low-and middle-income countries. Circulation 2016;133(21):2076-2085.
- 65. Marquina C, Zomer E, Vargas-Torres S, Zoungas S, Ofori-Asenso R, Liew D, et al. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics 2020;38(10):1095-1113.
- 66. Suh D-C, Griggs SK, Henderson ER, Lee S-M, Park T. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert Review of Pharmacoeconomics & Outcomes Research 2018;18(1):51-69.
- 67. (NICE) NIfHaCE. Guide to the methods of technology appraisal 2013. In; 04 April 2013. p. 94.
- 68. Lindh M, Banefelt J, Fox KM, Hallberg S, Tai M-H, Eriksson M, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. European Heart Journal Quality of Care and Clinical Outcomes 2019;5(3):225-232.
- 69. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of longterm exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. Journal of the American College of Cardiology 2012;60(25):2631-2639.
- 70. Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, et al. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence— An overview in the context of health decision-making. Journal of Clinical Epidemiology 2021;129:138-150.
- 71. Wu EQ, Zhou Z-Y, Xie J, Metallo C, Thokala P. Transparency in Health Economic Modeling: Options, Issues and Potential Solutions. PharmacoEconomics 2019;37(11):1349-1354.
- 72. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 2018;8(1):e016982.






Figure 1

Ezetimibe vs others

	Ezeumbe v3 outers			
		INB		Weight
Study		with 95% C		(%)
Kohli_2006	4,552 [-37,093,	46,198]	0.72
Ara_2008(1)	-622 [-42,268,	41,024]	0.72
Ara_2008(2)	-824 [-42,470,	40,822]	0.72
John Reckless_2010	756 [-1,349,	2,860]	10.07
Erkki Soini_2010	-1,351 [-3,776,	1,074]	9.96
Nooten_2011	5,273 [2,848,	7,698]	9.96
Laires_2015	2,137 [-10,521,	14,796]	4.63
Mihaylova_2016		-12,581,	12,736]	4.63
Kazi_2016(a)	←	-538,972,	459,904]	0.01
Kazi_2016(b)	< → 311,981 [-2,606,059,	3,230,021]	0.00
Kazi_2017	← -58,902 [-77,216,	-40,588]	2.88
Almalki_2017		-12,517,	12,800]	4.63
Davies_2017	3,298 [1,193,	5,402]	10.07
Stam-Slob _2017	5,622 [3,197,	8,047]	9.96
Korman_2018		23,584,	42,914]	6.03
Stam-Slob _2018	<> -25,493 [-152,858,	101,873]	0.08
Kongpakwattana_2019	< −5,709 [-1,047,336,	1,035,917]	0.00
Kongpakwattana_2019	<> -5,667 [-1,047,293,	1,035,960]	0.00
Kazi_2019(a)	2,564 [-10,396,	15,524]	4.51
Kazi_2019(b)	> 65,990 [46,272,	85,708]	2.58
Schlackow_2019(a)	3,068 [-38,577,	44,714]	0.72
Schlackow_2019(b)	912 [-11,746,	13,571]	4.63
Dressel_2019	<	-295,055,	179,264]	0.02
Landmesser_2020	6,020 [3,595,	8,446]	9.96
Han Yang_2020	1,145 [-18,961,	21,251]	2.51
Overall	• 4,274 [621,	7,927]	
Heterogeneity: τ^2 = 3.33e+07, I^2 = 84.21%, H^2 = 6.33	Not Cost-effective Cost-effective			
Test of $\theta_i = \theta_j$: Q(24) = 151.98, p = 0.00				
	-50000 0 50000			
Random-effects DerSimonian-Laird model	INB in US\$			

Sorted by: Year

Figure 2